Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin and Affective Function in Chronic Lower Back Pain Depression
NCT06355414Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of psilocybin in chronic low back pain (CLBP) and major depressive disorder (MDD) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Positive affect at 1 week, Negative affect at 1 week and 2 more. Started Apr 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
chronic low back pain (CLBP)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06355414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355414.